Journal ArticleDOI
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Jonathan W. Stewart,Andrew A. Nierenberg,Michael E. Thase,Louise Ritz,Melanie M. Biggs,Diane Warden,James F. Luther,Kathy Shores-Wilson,George Niederehe,Maurizio Fava +12 more
TLDR
After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.Abstract:
Background After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another. Methods We randomly assigned 727 adult outpatients with a nonpsychotic major depressive disorder who had no remission of symptoms or could not tolerate the SSRI citalopram to receive one of the following drugs for up to 14 weeks: sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg, sertraline (238 patients) at a maximal daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg. The study was conducted in 18 primary and 23 psychiatric care settings. The primary outcome was symptom remission, defined by a total score of 7 or less on the 17-item Hamilton Rating Scale for Depression (HRSD-17) at the end of the study. Scores on the Quick Inventory of Depressive Symptomatology — Self Report (QIDS-SR-16), obtained at treatment visits, de...read more
Citations
More filters
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: A multisite randomized controlled trial.
John P. O'Reardon,H. Brent Solvason,Philip G. Janicak,Shirlene Sampson,Keith E. Isenberg,Ziad Nahas,William M. McDonald,David H. Avery,Paul B. Fitzgerald,Colleen Loo,Mark A. Demitrack,Mark S. George,Harold A. Sackeim +12 more
TL;DR: Transcranial magnetic stimulation was effective in treating major depression with minimal side effects reported and offers clinicians a novel alternative for the treatment of this disorder.
PRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Journal ArticleDOI
Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology
Guy M. Goodwin,Peter M. Haddad,I. N. Ferrier,Jeffrey K Aronson,T R H Barnes,Andrea Cipriani,David Coghill,Seena Fazel,John R. Geddes,Heinz Grunze,Emily A. Holmes,Oliver D. Howes,S. Hudson,N. Hunt,Ian Jones,Iain Macmillan,H. McAllister-Williams,D. R. Miklowitz,Richard Morriss,Marcus R. Munafò,Carol Paton,B. J. Saharkian,Kate E. A. Saunders,Julia Sinclair,David Taylor,Eduard Vieta,Allan H. Young +26 more
TL;DR: The British Association for Psychopharmacology guidelines specify the scope and targets of treatment for bipolar disorder, and recommend strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment.
Journal ArticleDOI
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial
James W. Murrough,Dan V. Iosifescu,Lee C. Chang,Rayan K. Al Jurdi,Charles Green,Andrew M. Perez,Syed Z Iqbal,Sarah Pillemer,Alexandra Foulkes,Asim A Shah,Dennis S. Charney,Sanjay J. Mathew +11 more
TL;DR: Ketamine demonstrated rapid antidepressant effects in an optimized study design, further supporting NMDA receptor modulation as a novel mechanism for accelerated improvement in severe and chronic forms of depression.
References
More filters
Journal ArticleDOI
A rating scale for depression
TL;DR: The present scale has been devised for use only on patients already diagnosed as suffering from affective disorder of depressive type, used for quantifying the results of an interview, and its value depends entirely on the skill of the interviewer in eliciting the necessary information.
Journal ArticleDOI
Multiple imputation: a primer:
TL;DR: Essential features of multiple imputation are reviewed, with answers to frequently asked questions about using the method in practice.
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
A. John Rush,Madhukar H. Trivedi,Hicham M. Ibrahim,Thomas J. Carmody,Bruce A. Arnow,Daniel N. Klein,John C. Markowitz,Philip T. Ninan,Susan G. Kornstein,Rachel Manber,Michael E. Thase,James H. Kocsis,Martin B. Keller +12 more
TL;DR: The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings.